Lucid Capital Markets is acting as the sole book-running manager for the proposed offering.

Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at ...

Eli Lilly and Company’s LLY stock has risen 28% in the past three months. With exceptional growth from its GLP-1 drugs, ...

For reasons that are more than just obvious, the state education department has been at the receiving end of some of the most withering criticisms from the Naga ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...